Literature DB >> 1704686

Differences in immunoglobulin preparations for intravenous use: a comparison of six products.

B H Greenbaum1.   

Abstract

The use of intravenous gamma globulin products in both children and adults has increased markedly over the past 5 years, since these agents were licensed in the United States. Product competition has become fierce, with each supplier touting the merits of its own product. A summary of the six products currently available in the United States is presented. Comparisons are made according to method of product manufacture, product specifications, antibody titers, opsonization data, IgG subclass quantification, ease of administration, and side effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1704686     DOI: 10.1097/00043426-199024000-00015

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  4 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease.

Authors:  Ming-Chih Lin
Journal:  World J Pediatr       Date:  2014-05-07       Impact factor: 2.764

3.  Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults.

Authors:  Kevin B Laupland
Journal:  Can J Infect Dis       Date:  2002-03

4.  Management of Kawasaki disease in the British Isles.

Authors:  R Dhillon; L Newton; P T Rudd; S M Hall
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.